Tate & Lyle PLC
TATE & LYLE BOARD CHANGE
Tate & Lyle PLC announces that Kai Nargolwala has decided to step down as a
Non-Executive Director with effect from 31 December 2007.
Mr Nargolwala is based in Singapore and, as previously announced, will be
joining the Credit Suisse Group as Chief Executive Officer of the Asia-Pacific
Region on
1 January 2008. The requirements of this new executive role mean that he will no
longer be able to commit the required time to travel to the UK on a regular
basis to attend Tate & Lyle Board meetings. This has prompted his decision to
step down.
Sir David Lees, Chairman of Tate & Lyle, said: 'I am very sorry that Kai's new
work commitments make it necessary for him to step down from the Board. We thank
him for his excellent contribution over the past three years and wish him every
success in the future.'
Kai Nargolwala said, 'I am disappointed that the time commitments of my new
executive role mean I have to step down from the Board. I greatly enjoyed my
time with Tate & Lyle and wish the Company every success in the future'.
obile: 07798 837317
About Tate & Lyle:
Tate & Lyle is a world leading manufacturer of renewable food and industrial
ingredients. It uses innovative technology to transform corn and sugar into
value-added ingredients for customers in the food, beverage, pharmaceutical,
cosmetic, paper, packaging and building industries. The Company is a leader in
cereal sweeteners and starches, sugar refining, value added food and industrial
ingredients, and citric acid. Tate & Lyle is the world number-one in industrial
starches and is the sole manufacturer of SPLENDA(R) Sucralose.
Headquartered in London, Tate & Lyle is listed on the London Stock Exchange
under the symbol TATE.L. In the US its ADRs trade under TATYY. The Company
operates more than 50 production facilities throughout Europe, the Americas and
South East Asia. In the year to 31 March 2007, it employed 6,900 people in its
subsidiaries with a further 2,300 employed in joint ventures. Sales in the year
to 31 March 2007 totalled £4.0 billion. Additional information can be found on
http://www.tateandlyle.com.
SPLENDA(R) is a trademark of McNeil Nutritionals, LLC
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.